We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.

  • BMS Science Search BMS recruiting trials
  • Bolder Science Powered by ClinicalTrials.gov
    This website is intended for healthcare professionals
    This website is intended for healthcare professionals
  • Sign Up
  • Log In
  • Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
 
  • Clinical Trials
  • Molecular Pathways
  • About BMS Science
Cancel
    Sphingosine 1-Phosphate Receptor Type 1 (S1P-1R)
    • Immunology
    • BTK
    • CTLA-4
    • IL-13
    • MK2
    • PAD
    • S1PR
    • TLR 7/8
    • TYK2

    S1PR

    The ability of T cells to recirculate from lymph nodes to the blood and then into tissues is essential for the perpetuation of chronic inflammatory processes.1

    • Circulation of T cell subsets (naïve and central memory T cells) between lymph nodes and blood is mediated by two opposing receptors: Sphingosine 1-Phosphate Receptor Type 1 (S1P-1R) favors T cell egress while CC-chemokine receptor type 7 (CCR7) favors retention in the node.2,3
    • To egress from lymph nodes, the T cells require activation of S1P-1R by endothelial cell-generated S1P. S1P-1R activation overrides the lymph node retention effect of CCR7.2
    • Targeted modulation of S1P-1R causes aberrant internalization of the receptor and reduces the responsiveness of T cells to the S1P egress signal, favoring T cell retention in the lymph nodes.2

    References

    1. Bamias G, Clark DJ, Rivera-Nieves J. Curr Drug Targets. 2013;14(12):1490-1500.
    2. Brinkmann V, Billich A, Baumruker T, et al. Nat Rev Drug Discov. 2010;9(11):883-897.
    3. Pham THM, Okada T, Matloubian M, et al. Immunity. 2008;28(1):122-133.
    Bristol Myers Squibb logo
    • Legal Notice
    • Privacy Policy
    • Contact Us
    • Sitemap
    © 2022 BMS Science 01/22 466-US-2100214 BMS Science is a registered trademark of Bristol-Myers Squibb Company.

    You are now leaving www.BMSscience.com. BMS is not responsible for the content on third-party website

    Continue Cancel
    close-icon

    Log In

    Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

    Forgot Password

    Don't have an account? Sign Up

    close-icon

    Please enter your email address.

    You will receive a link to create a new password via email.

    Log In

    close-icon

    Create Account

    Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

    • 8 characters minimum
    • First character cannot be a number
    • Last character cannot be a number

    By clicking submit, you agree to the BMS Privacy Policy and Terms & Conditions

    close-icon

    Previous Next skip